Canadian Respiratory Journal / 2017 / Article / Tab 1

Research Article

Galactomannan in Bronchoalveolar Lavage Fluid for Diagnosis of Invasive Pulmonary Aspergillosis with Nonneutropenic Patients

Table 1

Baseline clinical characteristics of the study population.

IPA
(), (%)
Non-IPA
(), (%)

Age, mean years58.9755.62
Male gender20 (64.5)82 (53.9)
High-risk environment exposed2 (6.5)1 (0.7)
Underlying disease
 Emphysema5 (16.1)22 (14.5)
 COPD1 (3.2)8 (5.3)
 Bronchial asthma08 (5.3)
 Pulmonary tuberculosis2 (6.5)10 (6.6)
 Solid tumor3 (9.7)8 (5.3)
 Bronchiectasis3 (9.7)24 (15.8)
 Diabetes5 (16.1)16 (10.5)
 Liver cirrhosis01 (0.7)
 Hematologic malignancy01 (0.7)
 Autoimmune disease2 (6.5)2 (1.3)
 Kidney non-malignant disease03 (2.0)
 Organ failure2 (6.5)1 (0.7)
 No underlying disease9 (29.0)57 (37.5)
Final diagnosis
Proven: 0ABPA: 1 (0.7)
Probable: 10 (32.3)Aspergilloma: 3 (2.0)
Possible: 21 (67.7)Colonization or contamination: 5 (3.3)
Others: 143 (94.1)

IPA, invasive pulmonary aspergillosis; COPD, chronic obstructive pulmonary disease; ABPA, allergic bronchopulmonary aspergillosis. Date are number (%) of patients, unless otherwise indicated.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.